Justin Rhoades
About Justin Rhoades
Justin Rhoades is an Associate Computational Biologist at the Broad Institute in Cambridge, MA, where he has worked since 2016. He specializes in leveraging genomics and next-generation sequencing to investigate cancer biology and treatment resistance.
Work at Broad Institute
Justin Rhoades has been employed at the Broad Institute since 2016, serving as an Associate Computational Biologist. He is part of the Blood Biopsy Team, where he focuses on developing methods to detect and monitor cancer through circulating cell-free DNA (cfDNA) and liquid biopsies. His work leverages genomics and next-generation sequencing technologies to understand the molecular drivers of cancer and the mechanisms of resistance to treatment. This role highlights his commitment to advancing cancer research through innovative computational approaches.
Education and Expertise
Justin Rhoades holds a Bachelor of Science (B.S.) degree in Cell/Cellular and Molecular Biology from Binghamton University, which he completed from 2010 to 2014. He furthered his education at Boston University, earning a Master’s Degree in Bioinformatics from 2015 to 2016. His academic background provides a strong foundation for his work in computational biology, particularly in the areas of genomics and cancer research.
Background in Sound Engineering
Before his career in computational biology, Justin Rhoades worked as a Sound Engineer at Binghamton Sound, Staging, and Lighting from 2011 to 2014. This role involved technical expertise in sound production and management. Additionally, he served as an Undergraduate Teaching Assistant at Binghamton University in both 2013 and 2014, where he contributed to the educational development of fellow students.
Research Focus
Justin Rhoades is interested in leveraging genomics and next-generation sequencing to explore the molecular mechanisms underlying cancer. His research aims to identify the drivers of cancer and understand how tumors develop resistance to various treatments. This focus on cfDNA and liquid biopsies positions him at the forefront of cancer detection and monitoring methodologies.